Table 4. A list of kinases that preferentially inhibited (>50%) by bosutinib or Bos-I or those kinases equally inhibited (>50%) by both compounds.
| Bosutinib selective (>50% inhibitory activity) | Bos-I selective (>50% inhibitory activity) | Kinases inhibited in common (>50% inhibitory activity) |
|---|---|---|
| ALK | CAMK1g | ABL1 |
| CAMK2a | CHK1 | ABL2/ARG |
| CLK1 | FGFR1 | ACK1 |
| CLK3 | FGFR2 | ARK5/NUAK1 |
| DDR2 | FLT1/VEGFR1 | AXL |
| EPHB3 | FLT3 | BLK |
| IKKe/IKBKE | FLT4/VEGFR3 | BMX/ETK |
| MLCK/MYLK | IR | BTK |
| PHKg1 | IRR/INSRR | c-MER |
| STK33 | KDR/VEGFR2 | c-SRC |
| TBK1 | MELK | CAMK1d |
| TEC | MLCK2/MYLK2 | CHK2 |
| TRKA | MLK1/MAP3K9 | CK1d |
| TRKB | MLK2/MAP3K10 | CK1epsilon |
| ULK1 | NEK1 | CSK |
| ZAK/MLTK | NEK2 | DDR1 |
| PAK1 | EGFR | |
| PAK2 | EPHA2 | |
| PAK3 | EPHA3 | |
| PKCepsilon | EPHA4 | |
| PKCmu/PRKD1 | EPHA5 | |
| PKCnu/PRKD2 | EPHA6 | |
| RET | EPHA8 | |
| RSK4 | EPHB1 | |
| STK32B/YANK2 | EPHB2 | |
| TAK1 | EPHB4 | |
| TAOK1 | ERBB2/HER2 | |
| TTBK1 | ERBB4/HER4 | |
| TTBK2 | FES/FPS | |
| WEE1 | FGR | |
| FMS | ||
| FRK/PTK5 | ||
| FYN | ||
| GCK MAP4K2 | ||
| HCK | ||
| HGK/MAP4K4 | ||
| HPK1/MAP4K1 | ||
| KHS/MAP4K5 | ||
| LCK | ||
| LOK/STK10 | ||
| LRRK2 | ||
| LYN | ||
| LYN B | ||
| MARK4 | ||
| MEK1 | ||
| MEK2 | ||
| MEKK2 | ||
| MEKK3 | ||
| MINK/MINK1 | ||
| MLK3/MAP3K11 | ||
| MST1/STK4 | ||
| MST2/STK3 | ||
| MST3/STK24 | ||
| MST4 | ||
| MYO3b | ||
| NEK4 | ||
| PAK3 | ||
| PKCd | ||
| PYK2 | ||
| RSK3 | ||
| SIK1 | ||
| SIK2 | ||
| SLK/STK2 | ||
| STK25/YSK1 | ||
| SYK | ||
| TNIK | ||
| TRKC | ||
| TXK | ||
| TYK1/LTK | ||
| TYK2 | ||
| TYRO3/SKY | ||
| YES/YES1 |